SHUKRA MEDTECH LIMITED

₹81.58As of Sun 8 Nov 2026, 12:00 UTC

NSE:SHUKRAPHAR—

Country India

PE (Fwd) 105.9

TSR 10Y CAGR —

Div yield 0.01%

ROE —

Pharmaceutical Preparations

Beta (5Y) 0.55

PE TTM 163.2

TSR TTM —

Mkt cap ₹36.10B

ROIC —

SE Grade™

—

Value

—

Quality

Moat

—

1Y Price

Reference

₹89

—

9.22%

—

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

567.3

Revenue₹M

—

204.9

594.9

749.4

327.3

567.3

715.2

29.00%

73.31

Revenue growth%

—

190.41

25.96

(56.32)

73.31

26.08

49.63

—

100

72.06

Gross margin%

—

48.66

23.65

40.57

74.67

72.06

71.28

48.66

52.67

Operating margin%

—

6.22

7.83

26.17

38.04

52.67

52.72

26.17

38.88

Net margin%

—

3.66

7.41

24.74

29.25

38.88

39.00

24.74

163.2

P/E ratio (avg)x

—

129.0

—

120.5

EV/EBITx

—

95.44

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

100

0.50

EPS₹

—

0.12

0.66

0.42

0.22

0.50

0.63

42.92%

—

128.66

EPS growth%

—

446.67

(35.38)

(48.35)

128.66

26.46

46.64

—

100

—

Bookvalue per sh₹

—

FCF per share₹

—

0.01

Dividend per sh₹

—

0.01

0.10

0.01

(5.43%)

—

0.01

Div yield (avg)%

—

0.01

—

2.00

Payout ratio%

—

10.43

1.91

23.62

4.57

2.00

1.08

4.57

441.2

Shares (diluted)M

—

62.64

67.26

437.9

441.2

◌441.2

62.91%

(0.75)

Buyback yield%

—

(7.37)

(551.03)

—

(0.75)

◌—

(4.06)

—

D/E ratiox

—

35.99

Enterprise value₹B

—

35.99

—

LT debt₹M

—

Peers (US$374.4M)

Cap (US$)

Fermenta Biotech…

136.5M

25.81x

Bharat Parenterals…

136.0M

1,303x

Sudarshan Pharma…

86.44M

26.89x

Taho Pharmaceuticals…

372.8M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

27.34

23.90

Own earn%

—

Sh yield%

(0.74)

(4.06)

Owners

Insiders/Inst%

41.43

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

3/4

EPS growth years

2/4

Dividend streakyrs

Op margin range%

6–53

$1 testx

—

Incr. ROIC%

—

SHUKRA MEDTECH LIMITED engages in the manufacturing, marketing, and export of pharmaceutical formulations in India and internationally.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹567.3M

29.00%

1.00×

Cost of revenue

₹158.5M

10.80%

0.54×

Operating expenses

₹110.0M

6.05%

0.46×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m